Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352145 | 0.89 | L3MBTL1 (0.40) | AGXTFFAR1L3MBTL1PTGS2 | |
| SCHEMBL16352111 | 0.89 | L3MBTL1 (0.45) | L3MBTL1PTGS2 | |
| SCHEMBL16352153 | 0.85 | MAOB (0.43) | AGXTFFAR1FFAR4MMP1MMP2 | |
| SCHEMBL16352144 | 0.82 | SIGMAR1 (0.38) | — | |
| SCHEMBL16363712 | 0.81 | NR4A2 (0.40) | NR4A2AGXTFFAR1FFAR4AKR1B1 | |
| SCHEMBL16352124 | 0.81 | NR4A2 (0.40) | NR4A2AGXTFFAR1FFAR4AKR1B1 | |
| SCHEMBL16352159 | 0.80 | MRGPRX4 (0.39) | FFAR4MMP2MRGPRX4MMP9 | |
| SCHEMBL16352149 | 0.80 | FFAR4 (0.37) | FFAR1FFAR4L3MBTL1 | |
| SCHEMBL16352150 | 0.80 | ATM (0.44) | — | |
| SCHEMBL16352140 | 0.79 | HCAR2 (0.38) | AKR1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593136-B2 | Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase | THE GEORGE WASHINGTON UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | DCXR, G6PD, GRHPR | NR4A2 2395/4885AGXT 16/4885FFAR1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.